Prior work using gene expression profile to explain regional vulnerability to tau pathology focused on the regions exhibiting earliest proteinopathy rather than subsequent propagation ([11, 12]; Hyman, et al., 1984; [28]), whether using the suite of tau aggregation promoting genes [12] or noradrenergic neurotransmission related genes [27]. The gene discussed is MAPT; the disease is proteostasis deficiencies.